HRSA-26-052: Sickle Cell Disease Regional Care Excellence (SoRCE) Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2026.
Health Resources and Services Administration offered grants of up to $950,000 to nonprofits and colleges and universities. It expected to make about 7 awards worth $6.7 million in total. Applications closed on July 8, 2026.
From the official notice on Grants.gov, last changed June 5, 2026. Checked November 7, 2026.
- Award ceiling$950,000
- Total funding$6.7 million
- Expected awards7
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | June 5, 2026 |
|---|---|
| Deadline | July 8, 2026 |
| Archived by Grants.gov | August 30, 2026 |
Who can apply
This opportunity was open to nonprofits and colleges and universities.
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Hospitals or clinicsHealth centers.
Is this a realistic fit?
- Past Sickle Cell Treatment Demonstration Program awards averaged $5.4 million; this notice allows up to $950,000 per award.
- No cost sharing or match is required.
What the grant funds
Sickle Cell Disease Regional Care Excellence Program (SoRCE) is to improve the health of people with sickle cell disease (SCD) by expanding access to care, improving the quality of care, and tracking quality of life indicators. There are approximately 100,000 people in the United States with SCD. Treatment starting in early childhood can prevent or reduce complications such as severe pain episodes, silent strokes, and premature death. Despite universal identification at birth, fewer than half of children with SCD receive needed treatment. As these children become adolescents and transition to adulthood many are not appropriately identified as candidates for disease-modifying therapies, in part because their doctors are still learning how to use the latest treatments. The program is made up of seven regions with one award recipient per region serving as a Regional Coordinating Hub (RCH). Each award recipient will work with clinical and community-based partners in their region and engage in continuous quality improvement (CQI) initiatives to improve access and quality of care.
Who has won Sickle Cell Treatment Demonstration Program grants before
From fiscal 2021 to 2025, Sickle Cell Treatment Demonstration Program (93.365) awarded $27.0 million across 5 grant awards, an average of $5.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Alabama at Birmingham | Alabama | 1 | $6.2 million |
| The Johns Hopkins University | Maryland | 1 | $6.2 million |
| The Washington University | Missouri | 1 | $5.0 million |
| Childrens Hospital Medical Center | Ohio | 1 | $5.0 million |
| The Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders | California | 1 | $5.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-26-052 still open?
No. It closed on July 8, 2026.
Who can apply for Sickle Cell Disease Regional Care Excellence (SoRCE) Program?
Health Resources and Services Administration accepted applications from nonprofits and colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for Sickle Cell Disease Regional Care Excellence (SoRCE) Program?
Closed July 8, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $950,000 each. About $6.7 million in total across about 7 awards.
Who has won Sickle Cell Treatment Demonstration Program grants before?
The largest recipients over five fiscal years were University of Alabama at Birmingham, The Johns Hopkins University, The Washington University. The program made 5 awards worth $27.0 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)